Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating an investigational once-weekly medication designed to support weight reduction and improve sleep-related breathing.
Obstructive Sleep Apnea and Obesity
Age Range:
18
Gender:
Male and Female
Location:
Buffalo, New York
About the Study
This research study is evaluating an investigational medication administered once weekly by injection, to determine whether it can help reduce body weight and improve OSA severity.
Researchers will compare the investigational medicine to a placebo to assess its effects on breathing disruptions during sleep, weight loss, and overall health outcomes. The study will also evaluate the safety and tolerability of the investigational treatment.
Qualifications
You may qualify if you:
- Are 18 years of age or older.
- Have a diagnosis of moderate-to-severe obstructive sleep apnea.
- Do not have diabetes.
- Have overweight or obesity (BMI ≥27 kg/m²).
- Are either unable/unwilling to use PAP therapy or are currently using PAP therapy and plan to continue.
- Do not have certain sleep-related breathing disorders other than obstructive sleep apnea.
- Do not have significant or unstable medical conditions (such as recent cardiovascular events, severe kidney or liver disease, or uncontrolled endocrine disorders).
FEATURED STUDIES
An upcoming clinical research study is evaluating an investigational treatment designed to help prevent the flu in adults who may […]
An upcoming clinical research study is evaluating an investigational vaccine designed to help prevent illness caused by norovirus in adults […]
An upcoming clinical research study is evaluating an investigational long-acting approach designed to help prevent influenza. Join our interest list […]
Adults 65 and older may qualify for a clinical research study evaluating an investigational seasonal flu vaccine.
This clinical trial will help us learn if receiving another dose of the RSV vaccine is safe and can help […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]